These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

338 related articles for article (PubMed ID: 23216013)

  • 1. Clinical simulation model of long-acting opioids for treatment of chronic non-cancer pain in the United States.
    Neil N; Merchant S; Provenzano D; Ogden K; Mody SH
    J Med Econ; 2013; 16(2):307-17. PubMed ID: 23216013
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Budget impact analysis of tapentadol extended release for the treatment of moderate to severe chronic noncancer pain.
    Merchant S; Noe LL; Howe A; Duff S; Gricar J; Ogden K; Mody SH
    Clin Ther; 2013 May; 35(5):659-72. PubMed ID: 23587608
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Efficacy of tapentadol ER for managing moderate to severe chronic pain.
    Afilalo M; Morlion B
    Pain Physician; 2013 Jan; 16(1):27-40. PubMed ID: 23340531
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cost-effectiveness of tapentadol prolonged release compared with oxycodone controlled release in the UK in patients with severe non-malignant chronic pain who failed 1st line treatment with morphine.
    Ikenberg R; Hertel N; Moore RA; Obradovic M; Baxter G; Conway P; Liedgens H
    J Med Econ; 2012; 15(4):724-36. PubMed ID: 22364286
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cost-effectiveness of tapentadol in severe chronic pain in Spain: a cost analysis of data from RCTs.
    Obradovic M; Ikenberg R; Hertel N; Antoñanzas F; Gálvez R; Liedgens H
    Clin Ther; 2012 Apr; 34(4):926-43. PubMed ID: 22417717
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Composite measure to assess efficacy/gastrointestinal tolerability of tapentadol ER versus oxycodone CR for chronic pain: pooled analysis of randomized studies.
    Merchant S; Provenzano D; Mody S; Ho KF; Etropolski M
    J Opioid Manag; 2013; 9(1):51-61. PubMed ID: 23709304
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Clinical and economic evaluation of tapentadol extended release and oxycodone/naloxone extended release in comparison with controlled release oxycodone in musculoskeletal pain.
    Coluzzi F; Ruggeri M
    Curr Med Res Opin; 2014 Jun; 30(6):1139-51. PubMed ID: 24528146
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Tapentadol extended release for chronic pain patients.
    Taylor R; Pergolizzi JV; Raffa RB
    Adv Ther; 2013 Jan; 30(1):14-27. PubMed ID: 23328938
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Tapentadol immediate release versus oxycodone immediate release for treatment of acute low back pain.
    Biondi D; Xiang J; Benson C; Etropolski M; Moskovitz B; Rauschkolb C
    Pain Physician; 2013; 16(3):E237-46. PubMed ID: 23703422
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Tapentadol prolonged release versus strong opioids for severe, chronic low back pain: results of an open-label, phase 3b study.
    Gálvez R; Schäfer M; Hans G; Falke D; Steigerwald I
    Adv Ther; 2013 Mar; 30(3):229-59. PubMed ID: 23475406
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cost-effectiveness analysis of tapentadol immediate release for the treatment of acute pain.
    Kwong WJ; Ozer-Stillman I; Miller JD; Haber NA; Russell MW; Kavanagh S
    Clin Ther; 2010 Sep; 32(10):1768-81. PubMed ID: 21194601
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Imputing at-work productivity loss using results of a randomized controlled trial comparing tapentadol extended release and oxycodone controlled release for osteoarthritis pain.
    Lerner D; Chang H; Rogers WH; Benson C; Chow W; Kim MS; Biondi D
    J Occup Environ Med; 2012 Aug; 54(8):933-8. PubMed ID: 22850352
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Efficacy and safety of tapentadol extended release for the management of chronic low back pain: results of a prospective, randomized, double-blind, placebo- and active-controlled Phase III study.
    Buynak R; Shapiro DY; Okamoto A; Van Hove I; Rauschkolb C; Steup A; Lange B; Lange C; Etropolski M
    Expert Opin Pharmacother; 2010 Aug; 11(11):1787-804. PubMed ID: 20578811
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Safety and tolerability of tapentadol extended release in moderate to severe chronic osteoarthritis or low back pain management: pooled analysis of randomized controlled trials.
    Etropolski M; Kuperwasser B; Flügel M; Häufel T; Lange B; Rauschkolb C; Laschewski F
    Adv Ther; 2014 Jun; 31(6):604-20. PubMed ID: 24985410
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A pooled analysis of patient-specific factors and efficacy and tolerability of tapentadol extended release treatment for moderate to severe chronic pain.
    Etropolski M; Lange B; Goldberg J; Steup A; Rauschkolb C
    J Opioid Manag; 2013; 9(5):343-56. PubMed ID: 24353047
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cost-effectiveness analysis of oxycodone with naloxone versus oxycodone alone for the management of moderate-to-severe pain in patients with opioid-induced constipation in Canada.
    Goeree R; Goeree J
    J Med Econ; 2016; 19(3):277-91. PubMed ID: 26535790
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Efficacy and safety of Tapentadol extended release compared with oxycodone controlled release for the management of moderate to severe chronic pain related to osteoarthritis of the knee: a randomized, double-blind, placebo- and active-controlled phase III study.
    Afilalo M; Etropolski MS; Kuperwasser B; Kelly K; Okamoto A; Van Hove I; Steup A; Lange B; Rauschkolb C; Haeussler J
    Clin Drug Investig; 2010; 30(8):489-505. PubMed ID: 20586515
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Efficacy and safety of tapentadol prolonged release for moderate-to-severe chronic osteoarthritis knee pain: a pooled analysis of two double-blind, randomized, placebo- and oxycodone controlled release-controlled studies.
    Lange B; von Zabern D; Elling C; Dubois C
    Curr Med Res Opin; 2017 Aug; 33(8):1413-1422. PubMed ID: 28537506
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Efficacy and tolerability of tapentadol immediate release and oxycodone HCl immediate release in patients awaiting primary joint replacement surgery for end-stage joint disease: a 10-day, phase III, randomized, double-blind, active- and placebo-controlled study.
    Hartrick C; Van Hove I; Stegmann JU; Oh C; Upmalis D
    Clin Ther; 2009 Feb; 31(2):260-71. PubMed ID: 19302899
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Tapentadol prolonged release for managing moderate to severe, chronic malignant tumor-related pain.
    Kress HG; Koch ED; Kosturski H; Steup A; Karcher K; Lange B; Dogan C; Etropolski MS; Eerdekens M
    Pain Physician; 2014; 17(4):329-43. PubMed ID: 25054392
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.